Daily summary: possible coronavirus treatment, markets are optimistic

6:13 PM 5 February 2020
  • Unconfirmed coronavirus treatment

  • Major indices keep surging

  • Oil prices up almost 4%

  • Astonishing ADP data from the US

 

Another day brings us key news on coronavirus, which is crucial for the future global economy outlook. As of Wednesday, China’s officials confirmed more than 24,000 cases, resulting in almost 500 deaths. This time however, we might as well be a little bit optimistic as China’s TV reports about a possible drug that is about to treat people with the coronavirus.

 

Multiple reports of a possible treatment are regarded as a possible breakthrough by the markets. Major indices in the US and Europe are surging, the growth pace is not as impressive as yesterday, though. 

 

Worth mentioning is certainly the oil price. Both Brent and WTI are up almost 4%. An astonishing surge may result from a dose of optimism regarding coronavirus - a long-term demand in China might not collapse entirely. Moreover, OPEC allies are reportedly considering further output cuts to counter a possible drop in global oil demand.

 

As far as economic data is concerned, markets were surprised by terrific employment figures from the US. According to ADP, private payrolls rose by 291,000 in January, which is the highest increase since May 2015 and well above the 150,000 estimate. The figure may be viewed as a key indicator for the US economy and such astonishing growth helps the US dollar to gain against the euro. In addition to that, the ISM Non-Manufacturing Index was released. The latest reading showed a solid 55.5 points, beating 55.1 expectations. The latter also helps maintain a strong position of the US dollar.

Oil prices are up almost 4% today. Possible coronavirus treatment and alleged OPEC news may have had an impact. Source: xStation5

Share:
Back

Join over 1 600 000 XTB Group Clients from around the world

The financial instruments we offer, especially CFDs, can be highly risky. Fractional Shares (FS) is an acquired from XTB fiduciary right to fractional parts of stocks and ETFs. FS are not a separate financial instrument. The limited corporate rights are associated with FS.
This page was not created for investors residing in Brazil. This brokerage is not authorized by the Comissão de Valores Mobiliários (CVM) or the Brazilian Central Bank (BCB). The content of this page should not be characterized as an investment offer in Brazil or for investors residing in that country.
Losses can exceed deposits